The gross proceeds from the initial public offering are expected to be approximately $191 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding ...
WILMORE, Ky. (WKYT) - A Wilmore woman made quite the discovery after receiving results from a DNA kit, one that would lead to ...
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
DelveInsight's Airway Clearance Devices for Cystic Fibrosis Market Insights report provides the current and forecast market ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers ...
Cystic fibrosis is a genetic disorder that changes a vital protein in the body, causing a buildup of thick and sticky mucus, ...
Babies born in South Yorkshire are being tested for genetic conditions as part of an national study aimed at spotting rare ...
Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team ...
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...
Ann & Robert H. Lurie Children's Hospital of Chicago launched a newborn screening awareness campaign, with signage on public transit and billboards across Chicago urging parents to contact their child ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback